Wells Fargo’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-210,604
| Closed | -$15.2M | – | 7417 |
|
|
2025
Q4 | $15.2M | Sell |
210,604
-96,790
| -31% | -$6.25M | ﹤0.01% | 1711 |
|
|
2025
Q3 | $13.4M | Buy |
307,394
+51,796
| +20% | +$2.09M | ﹤0.01% | 1773 |
|
|
2025
Q2 | $7.26M | Buy |
255,598
+34,812
| +16% | +$1.04M | ﹤0.01% | 2174 |
|
|
2025
Q1 | $6.52M | Buy |
220,786
+48,216
| +28% | +$1.5M | ﹤0.01% | 2202 |
|
|
2024
Q4 | $5.02M | Sell |
172,570
-2,771
| -2% | -$116K | ﹤0.01% | 2444 |
|
|
2024
Q3 | $8.05M | Buy |
175,341
+41,468
| +31% | +$1.8M | ﹤0.01% | 2018 |
|
|
2024
Q2 | $5.47M | Sell |
133,873
-24,102
| -15% | -$692K | ﹤0.01% | 2178 |
|
|
2024
Q1 | $4.03M | Sell |
157,975
-32,753
| -17% | -$513K | ﹤0.01% | 2422 |
|
|
2023
Q4 | $1.73M | Sell |
190,728
-10,399
| -5% | -$69.5K | ﹤0.01% | 3023 |
|
|
2023
Q3 | $1.28M | Sell |
201,127
-22,771
| -10% | -$196K | ﹤0.01% | 3141 |
|
|
2023
Q2 | $2.48M | Buy |
223,898
+91,675
| +69% | +$1.15M | ﹤0.01% | 2727 |
|
|
2023
Q1 | $2.03M | Buy |
132,223
+78,896
| +148% | +$1.74M | ﹤0.01% | 2846 |
|
|
2022
Q4 | $1.18M | Sell |
53,327
-712
| -1% | -$10.6K | ﹤0.01% | 3135 |
|
|
2022
Q3 | $882K | Sell |
54,039
-28,505
| -35% | -$545K | ﹤0.01% | 3313 |
|
|
2022
Q2 | $1.2M | Buy |
82,544
+1,535
| +2% | +$22.8K | ﹤0.01% | 3171 |
|
|
2022
Q1 | $1.5M | Sell |
81,009
-44,761
| -36% | -$760K | ﹤0.01% | 3552 |
|
|
2021
Q4 | $2.99M | Buy |
125,770
+5,658
| +5% | +$135K | ﹤0.01% | 3096 |
|
|
2021
Q3 | $2.96M | Buy |
120,112
+53,403
| +80% | +$1.16M | ﹤0.01% | 3335 |
|
|
2021
Q2 | $1.65M | Sell |
66,709
-20,532
| -24% | -$478K | ﹤0.01% | 3859 |
|
|
2021
Q1 | $1.9M | Buy |
87,241
+6,317
| +8% | +$155K | ﹤0.01% | 3744 |
|
|
2020
Q4 | $2.06M | Buy |
80,924
+27,557
| +52% | +$804K | ﹤0.01% | 3476 |
|
|
2020
Q3 | $1.5M | Buy |
+53,367
| New | +$1.54M | ﹤0.01% | 3541 |
|
Other funds holding RNAM
Wells Fargo's RNAM Position: Q1 2026 in Review
Wells Fargo sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 210,604 shares — an estimated $15.2M sold.
Wells Fargo first reported a position in RNAM in Q3 2020 and held it in 22 quarters. The position peaked at $15.2M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Wells Fargo reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Wells Fargo sold 210,604 Avidity Biosciences shares in Q1 2026, an estimated $15.2M.
- Wells Fargo first reported a position in Avidity Biosciences in Q3 2020 and held it in 22 quarters.
- Wells Fargo's Avidity Biosciences position peaked at $15.2M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.